GT Biopharma shares rise 10.61% intraday after submitting IND application for GTB-5550 solid tumor therapy.
ByAinvest
Friday, Jan 16, 2026 9:31 am ET1min read
GTBP--
GT Biopharma Inc. surged 10.61% intraday after announcing the submission of an investigational new drug (IND) application for GTB-5550 TriKE, a B7-H3-targeted natural killer cell engager for solid tumor cancers. The IND submission, made in December 2025, marks the company’s expansion into a broader patient population, targeting a segment of the $362 billion global solid tumor market. The press release highlighted preliminary cash reserves of $7 million, extending the company’s runway into Q3 2026, which bolstered investor confidence. CEO Michael Breen emphasized the strategic significance of GTB-5550, noting its potential to leverage clinical learnings from GTB-3650 trials in hematologic malignancies. The stock’s sharp intraday gain aligns with the positive reception of the IND filing, reflecting optimism about the therapy’s development and market potential.
Stay ahead of the market.
Get curated U.S. market news, insights and key dates delivered to your inbox.
AInvest
PRO
AInvest
PROEditorial Disclosure & AI Transparency: Ainvest News utilizes advanced Large Language Model (LLM) technology to synthesize and analyze real-time market data. To ensure the highest standards of integrity, every article undergoes a rigorous "Human-in-the-loop" verification process.
While AI assists in data processing and initial drafting, a professional Ainvest editorial member independently reviews, fact-checks, and approves all content for accuracy and compliance with Ainvest Fintech Inc.’s editorial standards. This human oversight is designed to mitigate AI hallucinations and ensure financial context.
Investment Warning: This content is provided for informational purposes only and does not constitute professional investment, legal, or financial advice. Markets involve inherent risks. Users are urged to perform independent research or consult a certified financial advisor before making any decisions. Ainvest Fintech Inc. disclaims all liability for actions taken based on this information. Found an error?Report an Issue
Comments
No comments yet